EPO and anemia (phenotype): Serum ADMA levels were significantly decreased in CKD patients with anemia and treated with recombinant human erythropoietin (Epo) [56], which may indicate that the activated erythrocyte turnover reduced the accumulation of ADMA in erythrocytes.